FDA Drug Master File (DMF)

Q: What are the main types of Drug Master Files (DMFs)?

The FDA categorizes active DMFs into four main types: Type II: Drug Substances, Drug Substance Intermediates, or Finished Drug Products. Type III: Packaging Materials and Container-Closure Systems. Type IV: Excipients, Colorants, Flavors, or Essences. Type V: FDA-Accepted Reference Information.

Click the button below to see the service steps in an easy-to-follow graphic format.

Load Infographic Close

What is a Drug Master File (DMF)?

A Drug Master File (DMF) is a confidential submission to the FDA that provides detailed information on the facilities, processes, and materials used in the manufacturing, processing, packaging, and storage of human drug products. A DMF must be submitted by:

Drug manufacturers of finished drug products.
Manufacturers of active pharmaceutical ingredients (APIs).
Producers of excipients, inactive ingredients, or packaging materials used in drug products.

A DMF typically includes details about the components or ingredients, the process technology, and the quality control measures for the drug substance, excipient, or packaging material. DMFs can also contain other types of information (e.g., toxicology information and shared system, Risk Evaluation and Mitigation Data REMS)

Does FDA Review & Approve the DMF?

The FDA neither approves nor disapproves DMFs. Instead, it reviews their technical contents in connection with applications that reference them (e.g., NDAs, ANDAs, INDs, and BLAs). The DMF is critical in supporting the review and approval of finished product drugs in NDAs, ANDAs, and INDs. Therefore, expert DMF preparation is essential for a successful submission.

Drug Master Files are especially prevalent for APIs and drug packaging materials. The applicant for the finished drug product cites the earlier submitted DMF in their submission, enabling the FDA to evaluate the information regarding the API or packaging material independently from the finished drug product.

What are the different types of Drug Master Files?

● TYPE II: Drug products, substances, intermediates, or materials used in drug preparation.
● TYPE III: Packaging material.
●TYPE IV: Excipient, colorant, flavor, essence, or material used in their preparation.
● TYPE V: FDA accepted reference information.

Role of FDA Agent in Preparation of DMF

● Identification of test requirements for type II and III DMFs.
● Expert review and organize DMF information.
● Finalize and submit DMF to the FDA.
● Fulfill DMF FDA Agent role.
● Communicating with the FDA on behalf of the client.
● Cost estimation and FDA fee payment assistance (if needed)
● Submitting DMF Annual Reports and Closure Request to the FDA.

What is the DMF Submission Fee?

For Fiscal Year 2025, the FDA has set the Drug Master File (DMF) submission fee at $95,084. This fee applies specifically to Type II DMFs associated with Active Pharmaceutical Ingredients (APIs) under the Generic Drug User Fee Amendments (GDUFA) program. Other DMF types—such as Type III (packaging materials), Type IV (excipients), and Type V (FDA-accepted reference information)—do not require a submission fee. The fee for FY 2026 is projected to increase to $102,584.

What are the Drug Master File Components ?

A DMF submission must include FDA Form 39381, a cover letter, and administrative and technical details. The FDA website offers several templates to help prepare the administrative information. The initial submission should provide comprehensive administrative and technical information, while follow-up submissions should only include details about changes and updates. The relevant electronic Common Technical Document eCTD modules for a DMF submission generally consist of the following:

-Cover letter: submission type and DMF holder’s statement of commitment

-Administrative information: DMF holder’s name and address, the agent and the manufacturer’s name, site address, and contact info.

-References: An Authorization Letter (LOA) to the DMF permits an applicant or sponsor to reference the DMF in an FDA application.

-REMS: The Risk Evaluation and Mitigation Strategy documents must be provided when applicable.

Depending on the DMF type, additional eCTD modules, such as application status, meeting requests, information amendments, and labeling documents, may be provided.

How can FDA Listing Inc Assist ?

Compliance with FDA DMF requirements can be complex and time-consuming, often requiring specialized expertise. FDA Listing Inc. streamlines DMF preparation and submission, helping your firm meet FDA requirements in the following ways:

Assistance with the preparation and organization of DMF technical and administrative information.
Submission of DMFs (Type II–V) to the FDA, including eCTD formatting.
Serving as your FDA Agent for communication with the FDA and handling DMF-related correspondence.
Support with annual reports, amendments, and closure requests.

Please email or call us if you need assistance with DMF preparation, FDA Agent services, or any DMF-related matter.

Service Details & Fees

2,450 USD

4-5 Days

_______ Related Services _______

Frequently Asked Questions (FAQ)

Does the FDA review or approve a Drug Master File (DMF) upon submission?

No, the FDA does not formally “approve” or “disapprove” a DMF when it is filed. The FDA only reviews the technical content of a DMF when it is referenced by an applicant in a pending drug submission (such as an NDA, ANDA, or IND).

What is the main purpose of submitting a Drug Master File (DMF)?

A DMF allows raw material suppliers, active pharmaceutical ingredient (API) manufacturers, and packaging companies to submit confidential manufacturing and technical data directly to the FDA. This protects proprietary trade secrets while allowing generic or brand drug manufacturers to reference the information in their FDA applications.

What is a Letter of Authorization (LOA) for a DMF?

A Letter of Authorization (LOA) is an official document issued by the DMF holder that grants the FDA permission to review their confidential file on behalf of a specific drug applicant (such as an NDA or ANDA sponsor).

What are the main types of Drug Master Files (DMFs)?

The FDA categorizes active DMFs into four main types:

Type II: Drug Substances, Drug Substance Intermediates, or Finished Drug Products.
Type III: Packaging Materials and Container-Closure Systems.
Type IV: Excipients, Colorants, Flavors, or Essences.
Type V: FDA-Accepted Reference Information.

Do foreign Drug Master File holders need a U.S. Agent?

Yes, foreign companies holding or submitting a DMF are required to designate a U.S. Agent with a physical United States address to handle official communications, submission management, and regulatory inquiries with the FDA.

How must a Drug Master File be submitted to the FDA?

All initial DMF submissions, amendments, and required annual updates must be formatted according to Electronic Common Technical Document (eCTD) specifications and transmitted electronically through the FDA Electronic Submissions Gateway (ESG).